RT Journal Article
SR Electronic
T1 Effects of CPAP on Atherosclerotic Coronary Plaques in Patients with Sleep-Disordered Breathing: the ENTERPRISE Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.31.23294929
DO 10.1101/2023.08.31.23294929
A1 Fukase, Tatsuya
A1 Dohi, Tomotaka
A1 Kasai, Takatoshi
A1 Yanagisawa, Naotake
A1 Nishio, Ryota
A1 Takeuchi, Mitsuhiro
A1 Takahashi, Norihito
A1 Endo, Hirohisa
A1 Wada, Hideki
A1 Doi, Shinichiro
A1 Nishiyama, Hiroki
A1 Okai, Iwao
A1 Iwata, Hiroshi
A1 Koga, Seiji
A1 Okazaki, Shinya
A1 Miyauchi, Katsumi
A1 Daida, Hiroyuki
A1 Minamino, Tohru
YR 2023
UL http://medrxiv.org/content/early/2023/09/01/2023.08.31.23294929.abstract
AB Background The effects of continuous positive airway pressure (CPAP) treatment on coronary atheroma volume and vulnerability in patients with sleep-disordered breathing (SDB) coexisting with coronary artery disease are not well known. Thus, this study aimed to verify how CPAP treatment affects coronary plaques in patients with SDB who underwent percutaneous coronary intervention (PCI).Methods Altogether, fifty-three patients with SDB who underwent elective PCI using near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS) were randomly assigned to two groups based on CPAP use. This study evaluated the absolute changes in percentage atheroma volume (PAV) and total atheroma volume by IVUS, and the absolute changes in maximum lipid core burden index calculated for every 4-mm segment (maxLCBI4mm) using NIRS from baseline to 12 months, in addition to major adverse cardiac and cerebrovascular events (MACCE), and all-cause death.Results In the final analysis, 23 patients were allocated to the CPAP group, and 24 patients were allocated to the non-CPAP group. Compared with the non-CPAP group, the CPAP group had a significantly higher absolute change in PAV (−1.90±2.63% vs. 0.82±4.67%, p=0.018) and TAV (−20±35 mm3 vs. −2±21 mm3, p=0.041), and lower incidence rate of MACCE, mainly driven by a decrease in target lesion or non-target lesion target vessel revascularization (4% vs. 25%, p=0.037). In addition, adequate CPAP treatment resulted in greater plaque regression of −2.48%. However, there was no significant difference for absolute change in maxLCBI4mm (0 [−32, 40] vs. 34 [−71, 163], p=0.306) between the both groups, and no all-cause death was observed.Conclusions CPAP treatment for patients with SDB contributed to a decline in coronary plaque volume and prevention of revascularization risk but did not mitigate lipid-rich plaques. Especially, adequate CPAP treatment had a greater effect on coronary plaque regression.Clinical Trial Registration The Ethics Committee of the Juntendo Clinical Research and Trial Center approved this study (reference number 18-021), and which was registered with the UMIN (UMIN ID: R000036293). https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036293Clinical Perspective The effects of continuous positive airway pressure (CPAP) treatment on coronary atheroma volume and vulnerability in patients with sleep-disordered breathing (SDB) coexisting with coronary artery disease remains unclear. This study revealed that CPAP treatment for patients with SDB who underwent percutaneous coronary intervention contributed to a decline in coronary plaque volume and the prevention of cardiovascular events, mainly driven by a decrease in target vessel revascularization. In particular, adequate CPAP treatment may have a greater effect on coronary plaque regression; thus, it is important to focus on CPAP treatment and subsequent treatment compliance considering coronary plaques and events. In addition, patients with acute coronary syndrome who have greater plaque volume and lipid-rich plaques than those with stable coronary artery disease may benefit from the effects of adding CPAP treatment to optimal medical therapy due to an anti-atherogenic potential effect of CPAP treatment, thus, the further investigations targeting acute coronary syndrome are necessary.Competing Interest StatementTomotaka Dohi has received a research grant from Teijin Pharma Limited. Takatoshi Kasai and Hiroyuki Daida are affiliated with a department endowed by Philips Respironics, ResMed, and Fukuda Denshi. The remaining authors declare no conflicts of interest.Clinical TrialThis study was registered with the UMIN (UMIN ID: R000036293). https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036293Funding StatementThis research was supported by Teijin Pharma Limited and partially funded by KAKENHI (Grant Number 16K19431).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee (PR052/08, 07/064/797). The Ethics Committee of the Juntendo Clinical Research and Trial Center approved this study (reference number 18-021), which was registered with the University Hospital Medical Information Network (ID: R000036293).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets during and/or analyzed during the current study are available from the corresponding author with reasonable request.CPAPcontinuous positive airway pressureIVUSintravascular soundLCBI lipid core burden indexLDL-Clow-density lipoprotein cholesterolMACCEmajor adverse cardiac and cerebrovascular eventsMaxLCBI4mm/10mmmaximum lipid core burden index calculated for every 4-mm / 10-mm segmentNIRSnear-infrared spectroscopyPAVpercentage atheroma volumePCIpercutaneous coronary interventionSDBsleep-disordered breathing